CHARTER Longitudinal Neurocognitive Data Unveiled at AIDS 2014

Dr. Robert Heaton presents the longitudinal data from the CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) study at the 20th International AIDS Conference (AIDS 2014) being held from 20-25 July 2014 at the Melbourne Convention and Exhibition Centre, in Melbourne, Australia.

Key points of the presentation include that neurocognitive change (NC) change is common in HIV infection, there are clinical and biological predictors of NC change, that the increased comorbidity burden and factors associated with Hispanic ethnicity deserve more attention in clinical care of HIV+ individuals, and that consistent use of ART to maintain virologic control may protect the central nervous system and improve NC outcomes.

To Cite:

Heaton RK, Franklin DR, Deutsch R, Letendre SL, Ellis RJ, Blackstone K, Marquine MJ, Woods SP, Vaida F, Atkinson JH, Marcotte TD, McCutchan JA, Collier AC, Marra CM, Clifford DB, Gelmen BB, McArthur JC, Morgello S, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Smith DM, Grant I, for the CHARTER Group.  (IP). Neurocognitive change in the era of HIV combination antiretroviral therapy: A longitudinal CHARTER Study. 20th International AIDS Conference.